Entero Therapeutics, Inc.
Clinical-stage biopharma developing oral therapies for gastrointestinal diseases.
ENTO | US
Overview
Corporate Details
- ISIN(s):
- US33749P1012 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- 777 YAMATO ROAD, 33431 BOCA RATON
- Website:
- https://enterothera.com/
- Sector:
- Manufacturing
Description
Entero Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic, and orally delivered therapies for gastrointestinal (GI) diseases. The company's portfolio is centered on three proprietary technologies: latiglutenase, a first-in-class oral biotherapeutic designed to degrade gluten for patients with celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for GI indications such as gastroparesis; and adrulipase, a recombinant lipase enzyme to aid fat digestion in patients with exocrine pancreatic insufficiency resulting from cystic fibrosis or chronic pancreatitis. Entero's pipeline addresses a range of digestive disorders and autoimmune-related GI conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Entero Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Entero Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Entero Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
/other/Diamyd_Medical_AB_publ-logo.png){kind=logo}